{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:41:13Z","timestamp":1784976073657,"version":"3.55.0"},"reference-count":49,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["159497"],"award-info":[{"award-number":["159497"]}],"id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["37798"],"award-info":[{"award-number":["37798"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ontario Ministry of Research Innovation and Science; Early Research Award","award":["ER17-13-133"],"award-info":[{"award-number":["ER17-13-133"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,3]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>High-grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy characterized by resistance to chemotherapy and high rates of recurrence. HGSC tumors display a high prevalence of tumor suppressor gene loss. Given the type 1 interferon regulatory function of <jats:italic>BRCA1<\/jats:italic> and <jats:italic>PTEN<\/jats:italic>genes and their associated contrasting T-cell infiltrated and non-infiltrated tumor immune microenvironment (TIME) states, respectively, in this study we investigated the potential of stimulator of interferon genes (STING) pathway activation in improving overall survival via enhancing chemotherapy response, specifically in tumors with PTEN deficiency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Expression of PTEN protein was evaluated in tissue microarrays generated using pretreatment tumors collected from a cohort of 110 patients with HGSC. Multiplex immunofluorescence staining was performed to determine spatial profiles and density of selected lymphoid and myeloid cells. In vivo studies using the syngeneic murine HGSC cell lines, ID8-<jats:italic>Trp53<\/jats:italic>\n                     <jats:sup>\u2013\/\u2013<\/jats:sup>; <jats:italic>Pten<\/jats:italic>\n                     <jats:sup>\u2013\/\u2013<\/jats:sup> and ID8-<jats:italic>Trp53<\/jats:italic>\n                     <jats:sup>\u2013\/\u2013<\/jats:sup>; <jats:italic>Brca1<\/jats:italic>\n                     <jats:sup>\u2013\/\u2013<\/jats:sup>, were conducted to characterize the TIME and response to carboplatin chemotherapy in combination with exogenous STING activation therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patient tumors with absence of PTEN protein exhibited a significantly decreased disease specific survival and intraepithelial CD68+ macrophage infiltration as compared with intact PTEN expression. In vivo studies demonstrated that <jats:italic>Pten<\/jats:italic>-deficient ovarian cancer cells establish an immunosuppressed TIME characterized by increased proportions of M2-like macrophages, GR1+MDSCs in the ascites, and reduced effector CD8+ cytotoxic\u2009T-cell function compared with <jats:italic>Brca1<\/jats:italic>-deficient cells; further, tumors from mice injected with <jats:italic>Pten<\/jats:italic>-deficient ID8 cells exhibited an aggressive behavior due to suppressive macrophage dominance in the malignant ascites. In combination with chemotherapy, exogenous STING activation resulted in longer overall survival in mice injected with <jats:italic>Pten<\/jats:italic>-deficient ID8 cells, reprogrammed intraperitoneal M2-like macrophages derived from <jats:italic>Pten<\/jats:italic>-deficient ascites to M1-like phenotype and rescued CD8+ cytotoxic\u2009T-cell activation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study reveals the importance of considering the influence of cancer cell intrinsic genetic alterations on the TIME for therapeutic selection. We establish the rationale for the optimal incorporation of interferon activating therapies as a novel combination strategy in PTEN-deficient HGSC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-006170","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T13:25:22Z","timestamp":1680614722000},"page":"e006170","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04609579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04144140","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05070247","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Noor","family":"Shakfa","sequence":"first","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyang","family":"Li","sequence":"additional","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Conseil","sequence":"additional","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D","family":"Lightbody","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Wilson-Sanchez","sequence":"additional","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hamade","sequence":"additional","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chenard","sequence":"additional","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha A.","family":"Jawa","sequence":"additional","affiliation":[{"name":"Centre for Neuroscience Studies & School of Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Laight","sequence":"additional","affiliation":[{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"},{"name":"Pathology and Molecular Medicine, Queen's University Cancer Research Institute, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrakoma","family":"Afriyie-Asante","sequence":"additional","affiliation":[{"name":"Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Tyryshkin","sequence":"additional","affiliation":[{"name":"Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Koebel","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-2577","authenticated-orcid":false,"given":"Madhuri","family":"Koti","sequence":"additional","affiliation":[{"name":"Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada"},{"name":"Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"2025100313405826000_11.4.e006170.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2"},{"key":"2025100313405826000_11.4.e006170.2","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we stand?","volume":"13","author":"Leary","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2025100313405826000_11.4.e006170.3","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4880355","article-title":"Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy","volume":"2022","author":"Jin","year":"2022","journal-title":"J Oncol"},{"key":"2025100313405826000_11.4.e006170.4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cjp2.55","article-title":"STAT1-associated intratumoural Th1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer","volume":"2","author":"Au","year":"2016","journal-title":"J Pathol Clin Res"},{"key":"2025100313405826000_11.4.e006170.5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.81"},{"key":"2025100313405826000_11.4.e006170.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0011-2"},{"key":"2025100313405826000_11.4.e006170.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature14410"},{"key":"2025100313405826000_11.4.e006170.8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.211"},{"key":"2025100313405826000_11.4.e006170.9","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13678"},{"key":"2025100313405826000_11.4.e006170.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-Response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100313405826000_11.4.e006170.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0834-6"},{"key":"2025100313405826000_11.4.e006170.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07927-y","article-title":"BRCA2 deficiency instigates cgas-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity","volume":"10","author":"Heijink","year":"2019","journal-title":"Nat Commun"},{"key":"2025100313405826000_11.4.e006170.13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3311"},{"key":"2025100313405826000_11.4.e006170.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5"},{"key":"2025100313405826000_11.4.e006170.15","first-page":"1","article-title":"The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis","volume":"1\u20138","author":"Skelin","year":"2022","journal-title":"J Chemother"},{"key":"2025100313405826000_11.4.e006170.16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","article-title":"Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma","volume":"35","author":"Chen","year":"2019","journal-title":"Cancer Cell"},{"key":"2025100313405826000_11.4.e006170.17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0060"},{"key":"2025100313405826000_11.4.e006170.18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","article-title":"Sting agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100313405826000_11.4.e006170.19","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2817","article-title":"Generation of luciferase-expressing tumor cell lines","volume":"8","author":"Brennan","year":"2018","journal-title":"Bio Protoc"},{"key":"2025100313405826000_11.4.e006170.20","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000763"},{"key":"2025100313405826000_11.4.e006170.21","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","article-title":"The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer","volume":"54","author":"Garsed","year":"2022","journal-title":"Nat Genet"},{"key":"2025100313405826000_11.4.e006170.22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"2025100313405826000_11.4.e006170.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109412"},{"key":"2025100313405826000_11.4.e006170.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0526-8","article-title":"Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier","volume":"15","author":"Martins","year":"2014","journal-title":"Genome Biol"},{"key":"2025100313405826000_11.4.e006170.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0900-0"},{"key":"2025100313405826000_11.4.e006170.26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.trecan.2021.12.003","article-title":"When breaks get hot: inflammatory signaling in BRCA1\/2-mutant cancers","volume":"8","author":"van Vugt","year":"2022","journal-title":"Trends Cancer"},{"key":"2025100313405826000_11.4.e006170.27","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.99"},{"key":"2025100313405826000_11.4.e006170.28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100313405826000_11.4.e006170.29","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e29","article-title":"Chemokine network and overall survival in TP53 wild-type and mutant ovarian cancer","volume":"18","author":"Ignacio","year":"2018","journal-title":"Immune Netw"},{"key":"2025100313405826000_11.4.e006170.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215224","article-title":"Metabolic reprogramming in tumor-associated macrophages in the ovarian tumor microenvironment","volume":"14","author":"Kumar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025100313405826000_11.4.e006170.31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092220","article-title":"Tumor-associated macrophages and ovarian cancer: implications for therapy","volume":"14","author":"Schweer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025100313405826000_11.4.e006170.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.04.004"},{"key":"2025100313405826000_11.4.e006170.33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"2025100313405826000_11.4.e006170.34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002195","article-title":"Sting activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100313405826000_11.4.e006170.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005627","article-title":"Sting agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","volume":"11","author":"Ding","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100313405826000_11.4.e006170.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat Commun"},{"key":"2025100313405826000_11.4.e006170.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.12.001"},{"key":"2025100313405826000_11.4.e006170.38","doi-asserted-by":"crossref","unstructured":"Liang T , Chen J , Xu G , et al . Stat1 and CXCL10 involve in M1 macrophage polarization that may affect osteolysis and bone remodeling in extrapulmonary tuberculosis. Gene 2022;809. doi:10.1016\/j.gene.2021.146040","DOI":"10.1016\/j.gene.2021.146040"},{"key":"2025100313405826000_11.4.e006170.39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60646","article-title":"CXCL10\/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions","volume":"10","author":"Pandey","year":"2021","journal-title":"Elife"},{"key":"2025100313405826000_11.4.e006170.40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.062181799"},{"key":"2025100313405826000_11.4.e006170.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-019-0103-4","article-title":"Interferon-\u03b3 signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer","volume":"3","author":"Cardenas","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"2025100313405826000_11.4.e006170.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809784106"},{"key":"2025100313405826000_11.4.e006170.43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000979","article-title":"M2-Like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer","volume":"8","author":"Hensler","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313405826000_11.4.e006170.44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30568-1","article-title":"Sting agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"2025100313405826000_11.4.e006170.45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-022-01797-4","article-title":"The STING pathway: therapeutic vulnerabilities in ovarian cancer","volume":"127","author":"Shakfa","year":"2022","journal-title":"Br J Cancer"},{"key":"2025100313405826000_11.4.e006170.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003"},{"key":"2025100313405826000_11.4.e006170.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03073-0","article-title":"Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer","volume":"19","author":"Meng","year":"2021","journal-title":"J Transl Med"},{"key":"2025100313405826000_11.4.e006170.48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0818"},{"key":"2025100313405826000_11.4.e006170.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01041-y"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:41:09Z","timestamp":1759524069000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,4]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/jitc-2022-006170"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006170","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}